EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Tofacitinib versus methotrexate as the first‐line disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open‐label randomized controlled trial

Mohammad Mamun Khan, Shamim Ahmed, Md Kamrul Hasan Sajib iD, Abdullah All Morshed, Khandker Mahbub-Uz-Zaman, Syed Atiqul Haq

International Journal of Rheumatic Diseases · 2023

DOI: 10.1111/1756-185x.14801 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2023. Verfasst von Mohammad Mamun Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Delta Pharmaceuticals Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare tofacitinib and methotrexate (MTX) as first‐line disease‐modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA).

Methods

This open‐label, randomized controlled, parallel‐group, 3‐month trial randomly assigned 100 RA patients to tofacitinib 10 mg daily (49 patients) or MTX 25 mg subcutaneously weekly (51 patients). The primary end point was low disease activity (LDA) measured with Disease Activity Score‐28 with C‐reactive protein (DAS28‐CRP), and the secondary end point was LDA and remission measured by DAS28‐erythrocyte sedimentation rate (ESR), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Health Assessment Questionnaire Disability Index (HAQ‐DI) response and mean reduction of core set of outcomes from baseline at 12 weeks were also analyzed as secondary end points. In addition, acute‐phase reactants and composite measurements among groups were examined.

Results

LDA in DAS28‐CRP was achieved in 17 (34.7%) tofacitinib patients and 18 (35.3%) MTX patients ( p = .95). Fourteen (28.6%) and 11 (21.6%) tofacitinib and MTX patients, respectively, achieved LDA by DAS28‐ESR ( p = .42). Tofacitinib and MTX groups achieved LDA similarly in CDAI (36.7% against 37.3%; p = .96) and SDAI (38.8% vs. 39.2%; p = .96). There was no significant difference in achieving remission between the groups. At 12 weeks, tofacitinib reduced ESR and CRP ( p < .05). Composite measures and functional status decreased within groups but not between groups ( p > .05). Five (13.51%) tofacitinib patients developed hypertension. MTX caused gastrointestinal problems in 12 (30%) individuals. Two MTX (5%) and two tofacitinib (5.4%) patients had increased liver enzymes and renal impairment, respectively. Tofacitinib had 5.4% infection compared with 5% for MTX.

Conclusions

As tofacitinib may be more effective than MTX according to previous reports such as the ORAL Start study, high‐dose MTX (25 mg/week, subcutaneously) used in this study may be as efficacious as tofacitinib in patients with established RA who were DMARD naive or had not received a therapeutic dose of DMARDs. However, adverse effects differed between groups. Registered on: ClinicalTrials.gov; ID: NCT04464642.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansMethotrexateTreatment OutcomeDrug Therapy, CombinationDouble-Blind MethodPiperidinesPyrimidines

Stichwörter der Autor:innen

BangladeshDMARDsmethotrexaterheumatoid arthritistofacitinib

Substanzen

Antirheumatic AgentsMethotrexatetofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
  • Department of Rheumatology, Mymensingh Medical College Hospital, Mymensingh, Bangladesh.
  • Department of Rheumatology, Dhaka Medical College Hospital, Dhaka, Bangladesh.
  • Department of Rheumatology, Chittagong Medical College Hospital, Chittagong, Bangladesh.
  • Department of Rheumatology, Combined Military Hospital, Dhaka, Bangladesh.
  • Green Life Center for Rheumatic Care and Research, Dhaka, Bangladesh.

ORCID-Profile: Md Kamrul Hasan Sajib

Förderung

  • Delta Pharmaceuticals Ltd

Zitieren

APA

Khan, M. M., Ahmed, S., Hasan Sajib, M. K., Morshed, A. A., Mahbub-Uz-Zaman, K., & Haq, S. A. (2023). Tofacitinib versus methotrexate as the first‐line disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open‐label randomized controlled trial. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14801

Vancouver

Khan MM, Ahmed S, Hasan Sajib MK, Morshed AA, Mahbub-Uz-Zaman K, Haq SA. Tofacitinib versus methotrexate as the first‐line disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open‐label randomized controlled trial. International Journal of Rheumatic Diseases. 2023. doi:10.1111/1756-185x.14801

BibTeX
@article{Khan2023,
  author = {Khan, Mohammad Mamun and Ahmed, Shamim and Hasan Sajib, Md Kamrul and Morshed, Abdullah All and Mahbub-Uz-Zaman, Khandker and Haq, Syed Atiqul},
  title = {Tofacitinib versus methotrexate as the first‐line disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open‐label randomized controlled trial},
  journal = {International Journal of Rheumatic Diseases},
  year = {2023},
  doi = {10.1111/1756-185x.14801}
}
Kostenlos starten →